What is Beam Therapeutics's G&A?

Beam Therapeutics (BEAM) reported G&A of $34.43M in Q1 2026.

How has Beam Therapeutics's G&A changed year-over-year?

Beam Therapeutics's G&A increased by 23.2% year-over-year, from $27.94M to $34.43M.

What is the long-term trend for Beam Therapeutics's G&A?

Over 4 years (2021 to 2025), Beam Therapeutics's G&A has grown at a 18.8% compound annual growth rate (CAGR), from $57.22M to $113.82M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Beam Therapeutics BEAM G&A

G&A at other companies

CRISPR TherapeuticsCRSP

$17.18M-11.0%

Cogent Biosciences, Inc.COGT

$28.24M+137%

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Relay Therapeutics, Inc.RLAY

$11.03M-41.2%

Dyne Therapeutics, Inc.DYN

$24.39M+53.1%

Viking TherapeuticsVKTX

$13.98M-0.7%

Segments

By segment

See full

External General And Administrative Expenses$13.37M+149%

Employee Related Expenses$11.95M+14.5%

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

Operating cash flow-$128.5M-23.7%

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.51B+24.5%

Enterprise value$3.47B+51.2%

P/S21.4×-23.0×

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's G&A?: Beam Therapeutics (BEAM) reported G&A of $34.43M in Q1 2026.
How has Beam Therapeutics's G&A changed year-over-year?: Beam Therapeutics's G&A increased by 23.2% year-over-year, from $27.94M to $34.43M.
What is the long-term trend for Beam Therapeutics's G&A?: Over 4 years (2021 to 2025), Beam Therapeutics's G&A has grown at a 18.8% compound annual growth rate (CAGR), from $57.22M to $113.82M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.